SavedAdd your journal

Journals / Turkish Journal of Gastroenterology / 2017 / Cilt: 28 - Sayı: 6

Management of special patient groups with hepatitis B virus infection: The EASL 2017 Clinical Practice Guidelines

Ramazan İDİLMAN
Pages
518–521
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

In this brief report, based on European Association for the Study of the Liver 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection, the current optimal management of special patient groups with hepatitis B virus infection is summarized

📌 3 Key Takeaways

🎯
Objective & Hypothesis:The morbidity and mortality of hepatitis B virus-related liver disease are linked to the persistence of the hepatitis B virus replication.
📊
Key Findings & Data:Viral suppression with antiviral therapy has been shown to provide clinical benefits.
💡
Conclusion & Impact:In this brief report, based on European Association for the Study of the Liver 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection, the current optimal management of special patient groups with hepatitis B virus infection is summarized
🔬Design:Research Article
📍Scope:2017 Verileri
⚙️Variables:Domain Parameters

Özet

The morbidity and mortality of hepatitis B virus-related liver disease are linked to the persistence of the hepatitis B virus replication. Viral suppression with antiviral therapy has been shown to provide clinical benefits. Several special groups of patients with hepatitis B virus infection require special attention. In this brief report, based on European Association for the Study of the Liver 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection, the current optimal management of special patient groups with hepatitis B virus infection is summarized

🔖

Cite This Article

İDİLMAN, R. (2017). Management of special patient groups with hepatitis B virus infection: The EASL 2017 Clinical Practice Guidelines. Turkish Journal of Gastroenterology, Cilt: 28 - Sayı: 6, 518–521. https://ajindex.com/articles/410231

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (17)

  1. European Association for the Study of the Liver. EASL clinical practice guidelines: Management of chronic hepatitis B virus infection. J Hepatol 2012; 57: 167-85
  2. EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. J Hepatol 2017; 67: 370-98
  3. Stanaway JD, Flaxman AD, Naghavi M, et al. The global burden of viral hepatitis from 1990 to 2013: findings from the global burden disease study 2013. Lancet 2016; 388: 1081-8
  4. Lok AS, McMahon BJ. Chronic hepatitis B. Hepatology 2007; 45: 507-39
  5. Mutimer D. Review article: hepatitis B and liver transplantation. Aliment Pharmacol Ther 2006; 23: 1031-41
  6. Cholongitas E, Goulis J, Akriviadis E, Papatheodoridis GV. Hepatitis B immunoglobulin and/or nucleos(t)ide analogues for prophylaxis against hepatitis B virus recurrence after liver transplantation: a systematic review. Liver Transpl 2011; 17: 1176-90
  7. Roche B, Samuel D. Prevention of hepatitis B virus reinfection in liver transplant recipients. Intervirology 2014; 57: 196-201
  8. European Association for the Study of the Liver. EASL Clinical Practice Guidelines: Liver transplantation. J Hepatol 2016; 64: 433-85
  9. Fox AN, Terrault NA. The option of HBIG-free prophylaxis against recurrent HBV. J Hepatol 2012; 56: 1189-97
  10. Wang P, Tam N, Wang H, et al. Is hepatitis B immunoglobulin necessary in prophylaxis of hepatitis B recurrence after liver transplantation? A meta-analysis. PLoS One 2014; 9: e104480
  11. Heidrich B, Yurdaydin C, Kabacam G, et al. Late HDV RNA relapse after peginterferon alpha-based therapy of chronic hepatitis delta. Hepatology 2014; 60: 87-97
  12. EASL recommendations on treatment of hepatitis C 2016. J Hepatol 2017; 66: 153-94
  13. European AIDS Clinical Society. Treatment Guidelines 2016; 8: 1
  14. Lampertico, P, Maini M, Papatheodoridis G. Optimal management of hepatitis B virus infection - EASL Special conference. J Hepatol 2015; 63: 1238-53
  15. Chen HL, Lee CN, Chang CH, et al. Efficacy of maternal tenofovir disoproxil fumarate in interrupting mother-to-infant transmission of hepatitis B virus. Hepatology 2015; 62: 375-86
  16. Pan CQ, Duan Z, Dai E, et al. Tenofovir to prevent hepatitis B transmission in mothers with high viral load. N Engl J Med 2016; 374: 2324-34
  17. Reddy KR, Beavers KL, Hammond SP, et al. American gastroenterological association institute guideline on the prevention and treatment of hepatitis B virus reactivation during immunosuppressive drug therapy. Gastroent